Market Overview

UPDATE: Credit Suisse Initiates Jazz Pharmaceuticals with Outperform, $65 PT; Organic and Acquisition Growth Outlook

Share:
Related JAZZ
Jazz Pharma Downgraded By Vetr
Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?

Credit Suisse initiates its coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Outperform rating and a price target of $65.

Credit Suisse comments, "We rate JAZZ Outperform because it offers (1) organic growth of the Xyrem franchise, driven by volume growth, pricing power and what we see as a defensible franchise against generics until at least 2020, based on our work with patent counsel; (2) diversification, accretion and cash flows provided by Erwinaze, the key product obtained in the recently announced EUSA acquisition; and (3) a platform for acquisitions created by JAZZ's low tax rate, focused acquisition strategy and execution capabilities."

JAZZ closed at $43.66 on Tuesday.

Latest Ratings for JAZZ

DateFirmActionFromTo
May 2017RBC CapitalInitiates Coverage OnTop Pick
Apr 2017MizuhoDowngradesBuyNeutral
Feb 2017Evercore ISI GroupInitiates Coverage OnBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (JAZZ)

View Comments and Join the Discussion!